News

Hosted on MSN11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - MSN
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...
Hosted on MSN3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
MedCity News10mon
Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas
A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...
Reuters11mon
US FDA approves Novartis' kidney disease drug | Reuters
US FDA approves Novartis' kidney disease drug. By Sriparna Roy. August 7, 2024 10:29 PM UTC Updated August 7, 2024. The logo of Swiss drugmaker Novartis is pictured at the ...
MarketWatch11mon
Novartis says FDA gives accelerated approval for kidney-disease treatment
Novartis NVS said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...
AOL11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta ... - AOL
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...
Benzinga.com11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - Novartis (NYSE:NVS) - Benzinga
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.
Nasdaq3mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication ... FDA Approves Novartis Drug for Rare Kidney Disease Treatment March 21, 2025 — 02:10 pm EDT.
Benzinga.com3mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only ...
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.
Yahoo Finance11mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease - Yahoo Finance
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease. On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first ...